secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001558370-23-009622
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio Q1 net loss $16.7M, cash $58.8M; MB-106 trial data expected Q2
--------------------------------------------------------------------------

- Cash and cash equivalents $58.8M at Mar 31, 2023, down $17.9M from Dec 31, 2022.
- Net loss $16.7M ($2.06/share) vs $19.8M ($2.71/share) in Q1 2022; R&D expenses $14.0M.
- MB-106 (CD20 CAR T) shows 96% ORR and 75% CR in Fred Hutch trial; multicenter trial accruing.
- Orphan Drug Designation for MB-106 in Waldenstrom macroglobulinemia; pivotal Phase 2 may start Q1 2024.
- In April 2023, executed 15-for-1 reverse stock split and repaid $30.7M loan to Runway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023009622/0001558370-23-009622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023009622/tmb-20230512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer